RecruitingNot Applicable

Florbetaben for Imaging of Vascular Amyloid

Canada30 participantsStarted 2023-10-09

Plain-language summary

The Primary Objective is to determine if a new nuclear tracer (named 18F-Florbetaben) used with nuclear imaging (PET imaging) can detect inflamed plaque in patients with recent ACS or stroke/TIA.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. suffered a recent cardiovascular event (30-120 days post ACS (i.e. STEMI or NSTEMI) or TIA/stroke with ipsilateral large vessel atherosclerotic disease confirmed on US, CT or MRI;
✓. stable symptoms and hemodynamics;
✓. age \>/= 18 years;
✓. given informed consent.

Exclusion criteria

✕. a recent CV event likely to have been embolic in the opinion of the neurologist or cardiologist;
✕. severe LV dysfunction (EF\<30%);
✕. severe valve disease requiring intervention;
✕. decompensated heart failure;
✕. pregnancy (all women of child bearing potential will have a negative BHCG test;
✕. breastfeeding;
✕. women of childbearing potential who refuse to use two forms of contraception (this includes at least one form of highly effective and one effective method of contraception) throughout the study OR men capable of fathering a child who refuse to use contraception;.
✕. unable to give informed consent;.

What they're measuring

Feasibility of using 18F-Florbetaben PET in patients with recent ACS or stroke/TIA to detect inflammatory plaque

Timeframe: Within 16 weeks of vascular event

Trial details

NCT IDNCT06091319

SponsorOttawa Heart Institute Research Corporation

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-08-01

Contact for this trial

Kevin E Boczar, MD

6132821835 kboczar@ottawaheart.ca

View on ClinicalTrials.gov More Acute Coronary Syndrome trials